SLAMF7 and plasma cell myeloma: The phenotypic myeloma signature was further underscored by the observation that repeating the clinical stratification based on the drug responses of the CD138+/CD319+ plasma cell-marker-positive cells, which is the plasma cell class from the four-class CNN, did not significantly stratify the time to next treatment (Extended Data Fig. 9b).